Stock Track | Rhythm Pharma Soars 14% After Smashing Q3 Earnings Expectations

Stock Track11-06

Shares of Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) surged as much as 14.7% in early trading on Monday after the biopharmaceutical company reported better-than-expected financial results for the third quarter ended January 1.

Rhythm posted a quarterly revenue of $33.25 million, up 47.8% from the prior year period and beating analysts' consensus estimate of $32.52 million. The company's adjusted loss per share of $0.73 also came in narrower than the expected loss of $0.80 per share.

The strong Q3 performance added to a year of solid gains for Rhythm Pharma, with its shares already up 15.3% year-to-date heading into this earnings release. Analysts have remained bullish on the stock, with 10 out of 11 recommendations rating it as a "Buy" and the average price target standing at $64, according to data compiled by Refinitiv.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191229506?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 23:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191229506","market":"hk","top_or_hot":-1,"title":"Stock Track | Rhythm Pharma Soars 14% After Smashing Q3 Earnings Expectations","media":"Stock Track","content":"<p>Shares of Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) surged as much as 14.7% in early trading on Monday after the biopharmaceutical company reported better-than-expected financial results for the third quarter ended January 1.</p>\n\n<p>Rhythm posted a quarterly revenue of $33.25 million, up 47.8% from the prior year period and beating analysts' consensus estimate of $32.52 million. The company's adjusted loss per share of $0.73 also came in narrower than the expected loss of $0.80 per share.</p>\n\n<p>The strong Q3 performance added to a year of solid gains for Rhythm Pharma, with its shares already up 15.3% year-to-date heading into this earnings release. Analysts have remained bullish on the stock, with 10 out of 11 recommendations rating it as a \"Buy\" and the average price target standing at $64, according to data compiled by Refinitiv.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Rhythm Pharma Soars 14% After Smashing Q3 Earnings Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Rhythm Pharma Soars 14% After Smashing Q3 Earnings Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-06 23:44 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) surged as much as 14.7% in early trading on Monday after the biopharmaceutical company reported better-than-expected financial results for the ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RYTM","symbol_name":"Rhythm Pharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1191229506","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191229506","pubTimestamp":1730907859,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Rhythm Pharmaceuticals Inc.  surged as much as 14.7% in early trading on Monday after the biopharmaceutical company reported better-than-expected financial results for the third quarter ended January 1.Rhythm posted a quarterly revenue of $33.25 million, up 47.8% from the prior year period and beating analysts' consensus estimate of $32.52 million. The company's adjusted loss per share of $0.73 also came in narrower than the expected loss of $0.80 per share.The strong Q3 performance ad","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RYTM":"Rhythm Pharmaceuticals Inc."},"translate_title":"股票轨迹Rhythm Pharma第三季度盈利超出预期后飙升14%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RYTM":1},"content_text":"Shares of Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) surged as much as 14.7% in early trading on Monday after the biopharmaceutical company reported better-than-expected financial results for the third quarter ended January 1.\nRhythm posted a quarterly revenue of $33.25 million, up 47.8% from the prior year period and beating analysts' consensus estimate of $32.52 million. The company's adjusted loss per share of $0.73 also came in narrower than the expected loss of $0.80 per share.\nThe strong Q3 performance added to a year of solid gains for Rhythm Pharma, with its shares already up 15.3% year-to-date heading into this earnings release. Analysts have remained bullish on the stock, with 10 out of 11 recommendations rating it as a \"Buy\" and the average price target standing at $64, according to data compiled by Refinitiv.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191229506"}